More than half of the patients who received treatment survived, scientists reported.
Two of the first 16 people to receive an experimental treatment for Ebola have recovered in the current outbreak in North Kivu and Ituri provinces of the Democratic Republic of Congo.
The four additional treatments approved by Congo’s ethics committee are Remdesivir, made by Israel’s Gilead Sciences; ZMapp, an intravenous treatment made by San Diego’s Mapp Pharmaceutical; Japanese drug Favipiravir; and one referred to as Regn3450 – 3471 – 3479.
This intermediate level course is for clinicians caring for patients with suspected or confirmed Ebola virus disease. Modules provide information on screening and triage, infection prevention and control, laboratory diagnostics, organization of the Ebola Treatment Centre (ETC), clinical care of patients in the ETC, and investigational therapeutic agents.
On June 4, the Democratic Republic of the Congo approved the use of favipiravir, a drug originally developed to fight influenza, for treating Ebola patients.
Five experimental medicines are poised to undergo a real-life clinical trial against the Ebola virus at makeshift treatment centers in remote areas of the Democratic Republic of Congo.
The World Health Organization (WHO) hopes to get government approval within days to use five experimental drugs to treat Ebola patients, in a clinical trial which could lay the foundation for rapid treatment in any future outbreaks.
The Phase 1 clinical trial is examining the safety and tolerability of a single monoclonal antibody called mAb114, which was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID).
The experimental treatment is made from an antibody isolated from the blood of a man who survived Ebola infection during the 1995 outbreak in the Congo.
International health organizations are in discussions with the Democratic Republic of Congo about how and whether to deploy treatments in addition to a vaccine.